Craneware plc
Craneware plc (CRWRF) Stock Overview
Explore Craneware plc’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
1B
P/E Ratio
88.35
EPS (TTM)
$0.42
ROE
0.04%
CRWRF Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Craneware plc (CRWRF) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $36.46.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 88.35 and a market capitalization of 1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company provides solutions, such as Trisus pricing transparency software; Trisus Pricing Analyzer, a solution that simplifies and automates the price modeling process; Trisus Chargemaster, an automated chargemaster management solution; InSight Medical Necessity, a solution that offers medical necessity for the United States payors; Trisus Claims Informatics, a retrospective charge capture analytical application that identifies areas of risk for its team to investigate; Trisus Supply, a solution that improves supplies reimbursement; and InSight Audit, an audit management solution for government and commercial payors. It also offers InSight Denials to analyze, track, trend, and report on denial data; Trisus Healthcare Intelligence, a solution that provides insights into resource consumption on the patient level; Trisus Medication Analytic solutions; and Trisus supplies assistant solutions. In addition, the company provides Sentinel, a drug tracking solution; Sentrex, a SaaS-based solution that helps covered entities expand medication access; Sentrex 330; Referral Verification System; and Sentry Core, a solution that simplifies the complexities of pharmacy procurement, utilization, and compliances. Further, it offers appeal and professional services. Craneware plc was incorporated in 1999 and is headquartered in Edinburgh, the United Kingdom.
Keith Neilson
747
1 Tanfield, Edinburgh
2012